Search hospitals > Virginia > Charlottesville

University of Virginia Cancer Center

Claim this profile
Charlottesville, Virginia 22903
Global Leader in Lung Cancer
Global Leader in Ovarian Cancer
Conducts research for Cancer
Conducts research for Breast Cancer
Conducts research for Brain Tumor
483 reported clinical trials
31 medical researchers
Photo of University of Virginia Cancer Center in CharlottesvillePhoto of University of Virginia Cancer Center in CharlottesvillePhoto of University of Virginia Cancer Center in Charlottesville

Summary

University of Virginia Cancer Center is a medical facility located in Charlottesville, Virginia. This center is recognized for care of Lung Cancer, Ovarian Cancer, Cancer, Breast Cancer, Brain Tumor and other specialties. University of Virginia Cancer Center is involved with conducting 483 clinical trials across 543 conditions. There are 31 research doctors associated with this hospital, such as William C. Petersen, Linda Duska, MD, Richard D. Hall, and Matthew J. Reilley.

Area of expertise

1Lung Cancer
Global Leader
University of Virginia Cancer Center has run 70 trials for Lung Cancer. Some of their research focus areas include:
Stage IV
Stage III
EGFR positive
2Ovarian Cancer
Global Leader
University of Virginia Cancer Center has run 65 trials for Ovarian Cancer. Some of their research focus areas include:
Stage IV
Stage III
BRCA1 positive

Top PIs

Clinical Trials running at University of Virginia Cancer Center

Lung Cancer
Cancer
Skin Cancer
Ovarian Cancer
Prostate Cancer
Non-Small Cell Lung Cancer
Testicular cancer
Acute Myeloid Leukemia
Wilms Tumor
Bladder Cancer
Image of trial facility.

Chemotherapy + Immunotherapy vs. Immunotherapy

for Advanced Lung Cancer

This phase III trial compares the effect of adding chemotherapy to immunotherapy (pembrolizumab) versus immunotherapy alone in treating patients with stage IIIB-IV lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab and chemotherapy may help stabilize lung cancer.
Recruiting2 awards Phase 3
Image of trial facility.

Osimertinib + Bevacizumab

for Lung Cancer

This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting2 awards Phase 331 criteria
Image of trial facility.

Immunotherapy + Chemotherapy

for Non-Small Cell Lung Cancer

This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at University of Virginia Cancer Center?
Where is University of Virginia Cancer Center located?
Who should I call to ask about financial aid or insurance network?
What insurance does University of Virginia Cancer Center accept?
What awards or recognition has University of Virginia Cancer Center received?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security